Targeting Protein Kinase C in Glioblastoma Treatment.
enzastaurin
epidermal growth factor receptor
glioblastoma
glioma stem cells
neural stem cells
neuregulin
neurogenesis
protein kinase C
temozolomide
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
04 Apr 2021
04 Apr 2021
Historique:
received:
22
02
2021
revised:
29
03
2021
accepted:
31
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associated with a poor prognosis. Despite the use of combined treatment approaches, recurrence is almost inevitable and survival longer than 14 or 15 months after diagnosis is low. It is therefore necessary to identify new therapeutic targets to fight GBM progression and recurrence. Some publications have pointed out the role of glioma stem cells (GSCs) as the origin of GBM. These cells, with characteristics of neural stem cells (NSC) present in physiological neurogenic niches, have been proposed as being responsible for the high resistance of GBM to current treatments such as temozolomide (TMZ). The protein Kinase C (PKC) family members play an essential role in transducing signals related with cell cycle entrance, differentiation and apoptosis in NSC and participate in distinct signaling cascades that determine NSC and GSC dynamics. Thus, PKC could be a suitable druggable target to treat recurrent GBM. Clinical trials have tested the efficacy of PKCβ inhibitors, and preclinical studies have focused on other PKC isozymes. Here, we discuss the idea that other PKC isozymes may also be involved in GBM progression and that the development of a new generation of effective drugs should consider the balance between the activation of different PKC subtypes.
Identifiants
pubmed: 33916593
pii: biomedicines9040381
doi: 10.3390/biomedicines9040381
pmc: PMC8067000
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : European Regional Development Fund
ID : ITI-0042-2019
Organisme : Consejería de Salud y Familias, Junta de Andalucía
ID : ITI-0042-2019
Organisme : Integrated Territorial Investment Operational Programe of the European Commission
ID : ITI-0042-2019
Références
Cell Rep. 2020 Sep 29;32(13):108196
pubmed: 32997991
J Biol Chem. 1996 Jun 7;271(23):13504-14
pubmed: 8662863
Int J Oncol. 1999 Aug;15(2):237-43
pubmed: 10402232
Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L429-38
pubmed: 10956616
Crit Rev Biochem Mol Biol. 2018 Apr;53(2):208-230
pubmed: 29513138
J Neurobiol. 1998 Aug;36(2):234-48
pubmed: 9712307
Neurochem Res. 2009 Dec;34(12):2055-66
pubmed: 19856100
Neuropathol Appl Neurobiol. 2018 Feb;44(2):172-184
pubmed: 28574607
Clin Cancer Res. 1996 Apr;2(4):619-22
pubmed: 9816211
J Biol Chem. 1991 Mar 15;266(8):4661-4
pubmed: 2002013
J Biol Chem. 2002 Jun 14;277(24):22073-84
pubmed: 11934885
Anticancer Res. 2013 Aug;33(8):3383-9
pubmed: 23898108
Cancer Sci. 2020 Jun;111(6):1979-1990
pubmed: 32259365
Neuro Oncol. 1999 Jan;1(1):44-51
pubmed: 11550301
Cancers (Basel). 2015 Sep 03;7(3):1758-84
pubmed: 26404379
Front Cell Dev Biol. 2019 Mar 20;7:39
pubmed: 30949480
Int J Biochem Cell Biol. 2005 Apr;37(4):715-9
pubmed: 15694831
Front Oncol. 2021 Jan 29;10:614295
pubmed: 33585240
J Clin Oncol. 2010 Mar 1;28(7):1168-74
pubmed: 20124186
Neuro Oncol. 2010 Feb;12(2):181-9
pubmed: 20150385
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Acta Neuropathol. 2013 Sep;126(3):443-51
pubmed: 23904111
J Comp Neurol. 2011 Mar 1;519(4):690-713
pubmed: 21246550
Cancer Res. 2009 Sep 15;69(18):7243-51
pubmed: 19738068
Cell Cycle. 2009 Oct 15;8(20):3274-84
pubmed: 19770585
Clin Cancer Res. 2009 May 15;15(10):3617-23
pubmed: 19417015
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10159-63
pubmed: 1438205
Neurosurg Focus. 2014 Dec;37(6):E15
pubmed: 25434384
Neuro Oncol. 2005 Oct;7(4):436-51
pubmed: 16212809
Cancer Biol Ther. 2008 Sep;7(9):1321-5
pubmed: 18836294
Sci Signal. 2009 Jan 27;2(55):ra4
pubmed: 19176518
Biochim Biophys Acta. 2011 Jun;1813(6):1190-7
pubmed: 21419810
Cancer Res. 1991 Oct 1;51(19):5355-60
pubmed: 1913657
Carcinogenesis. 2010 Feb;31(2):311-7
pubmed: 19965895
J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15
pubmed: 18091559
Eur J Neurosci. 2009 Jul;30(1):9-24
pubmed: 19558606
Neurol Med Chir (Tokyo). 2014;54(4):302-9
pubmed: 24390189
Cell Stem Cell. 2010 Aug 6;7(2):150-61
pubmed: 20682444
J Biol Chem. 2002 Sep 20;277(38):35150-5
pubmed: 12130632
J Neurochem. 2009 Apr;109(1):203-13
pubmed: 19187446
Front Cell Neurosci. 2014 Nov 27;8:396
pubmed: 25505873
J Oncol. 2012;2012:537861
pubmed: 22973309
J Neurosci. 1997 Jul 1;17(13):5046-61
pubmed: 9185542
Toxins (Basel). 2016 May 28;8(6):
pubmed: 27240402
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Ann Oncol. 2017 Jul 1;28(7):1457-1472
pubmed: 28863449
Acta Neuropathol. 2014 Oct;128(4):561-71
pubmed: 25008768
J Nat Prod. 2019 Sep 27;82(9):2517-2528
pubmed: 31507181
Neuro Oncol. 2002 Jan;4(1):9-21
pubmed: 11772428
J Neurooncol. 2016 Mar;127(1):127-35
pubmed: 26643807
Cold Spring Harb Perspect Biol. 2016 May 02;8(5):
pubmed: 27048191
Dev Biol. 2006 Mar 15;291(2):300-13
pubmed: 16458284
BMC Cancer. 2014 Feb 14;14:90
pubmed: 24528676
Acta Neuropathol. 2012 Nov;124(5):615-25
pubmed: 22886134
Chem Rev. 2001 Aug;101(8):2353-64
pubmed: 11749377
Neuro Oncol. 2012 Mar;14(3):344-50
pubmed: 22291006
J Biol Chem. 2011 May 20;286(20):17704-13
pubmed: 21454702
Int J Oncol. 2019 Oct;55(4):879-895
pubmed: 31485609
Curr Opin Oncol. 2007 Nov;19(6):590-5
pubmed: 17906457
Stem Cells Int. 2016;2016:2759403
pubmed: 27738435
Science. 1992 Mar 27;255(5052):1707-10
pubmed: 1553558
J Neurooncol. 2017 Sep;134(3):505-512
pubmed: 28233083
Front Immunol. 2013 Jan 17;3:423
pubmed: 23335926
Signal Transduct Target Ther. 2017 Sep 29;2:17040
pubmed: 29263927
J Clin Oncol. 1999 Feb;17(2):645-50
pubmed: 10080610
Eur J Cancer. 1992;28A(4-5):805-10
pubmed: 1524899
Cancer Cell. 2007 Jan;11(1):69-82
pubmed: 17222791
Brain Res Bull. 2002 Apr;57(6):751-8
pubmed: 12031271
Neuropathol Appl Neurobiol. 2016 Dec;42(7):621-638
pubmed: 27424496
Neuro Oncol. 2015 Sep;17(9):1270-4
pubmed: 25605819
Br J Pharmacol. 2017 Jul;174(14):2373-2392
pubmed: 28476069
Cancer Chemother Pharmacol. 2002 Jan;49(1):69-77
pubmed: 11855754
Cell. 2000 Oct 13;103(2):211-25
pubmed: 11057895
Oncogene. 2004 Dec 2;23(56):9062-9
pubmed: 15489897
Cancer Res. 2020 Feb 15;80(4):709-718
pubmed: 31806641
Nutrients. 2018 Apr 06;10(4):
pubmed: 29642372
Mol Cell Biol Res Commun. 2000 Aug;4(2):106-10
pubmed: 11170840
J Biol Chem. 1997 Jan 31;272(5):2927-35
pubmed: 9006938
Cell Stem Cell. 2009 Jun 5;4(6):568-80
pubmed: 19497285
Science. 1962 Mar 30;135(3509):1127-8
pubmed: 13860748
BMC Cancer. 2018 Feb 13;18(1):185
pubmed: 29439667
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9776-81
pubmed: 23720309
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
J Pathol. 2012 Jan;226(1):7-16
pubmed: 22072542
Nature. 2010 Dec 9;468(7325):824-8
pubmed: 21102434
J Comp Neurol. 2006 Jan 20;494(3):415-34
pubmed: 16320258
J Neurosci. 2002 Feb 1;22(3):629-34
pubmed: 11826091
Oncogene. 2004 Dec 16;23(58):9392-400
pubmed: 15558011
Acta Neuropathol. 2014 Oct;128(4):551-9
pubmed: 25143301
J Pediatr Neurosci. 2017 Jul-Sep;12(3):237-244
pubmed: 29204198
Cancer Res. 2007 May 1;67(9):4010-5
pubmed: 17483311
Cell. 2013 Jan 31;152(3):599-611
pubmed: 23374352
J Neurosci. 1996 Mar 15;16(6):2027-33
pubmed: 8604047
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
FASEB J. 1999 Oct;13(13):1658-76
pubmed: 10506570
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
J Natl Cancer Inst. 1972 Feb;48(2):347-56
pubmed: 4347034
Neuro Oncol. 2013 Jan;15(1):91-6
pubmed: 23095230
Cancer Res. 2005 Aug 15;65(16):7462-9
pubmed: 16103100
Nat Rev Mol Cell Biol. 2010 Feb;11(2):103-12
pubmed: 20094051
Cell Death Dis. 2020 Apr 22;11(4):262
pubmed: 32321920
Cell. 2013 Jun 6;153(6):1219-1227
pubmed: 23746839
J Oncol. 2012;2012:376894
pubmed: 22685459
Cell Signal. 2021 Jan;77:109819
pubmed: 33147518
Nat Rev Neurol. 2019 Jul;15(7):405-417
pubmed: 31227792
Sci Rep. 2016 Jul 01;6:28873
pubmed: 27364328
Cell Cycle. 2013 Jun 1;12(11):1649-50
pubmed: 23673324
Int J Mol Sci. 2021 Jan 08;22(2):
pubmed: 33435537
Neuron. 2018 Apr 18;98(2):246-248
pubmed: 29673477
Trends Neurosci. 2003 Nov;26(11):590-6
pubmed: 14585598
Nat Rev Neurol. 2017 Jun;13(6):340-351
pubmed: 28497806
Neuro Oncol. 2005 Jan;7(1):32-40
pubmed: 15701280
Science. 2004 May 28;304(5675):1338-40
pubmed: 15060285
Oncogene. 2008 Jun 5;27(25):3587-95
pubmed: 18212741
Neuropsychopharmacology. 2021 May;46(6):1207-1219
pubmed: 33335309
Oncogene. 2007 May 3;26(20):2885-93
pubmed: 17146445
Sci Rep. 2018 May 9;8(1):7352
pubmed: 29743610
J Neurosci. 2009 Apr 8;29(14):4605-15
pubmed: 19357285
Oncogene. 2019 Jan;38(1):120-139
pubmed: 30082911
Cell Cycle. 2010 Aug 1;9(15):3012-21
pubmed: 20714216
J Med Life. 2009 Oct-Dec;2(4):386-93
pubmed: 20108752
Biomed Res Int. 2014;2014:725921
pubmed: 24834433
Am J Transl Res. 2013 Sep 25;5(6):563-81
pubmed: 24093054
Nat Med. 1998 Nov;4(11):1313-7
pubmed: 9809557
Oncogene. 2001 Nov 1;20(50):7398-407
pubmed: 11704869
Cancer Res. 1990 Nov 15;50(22):7134-8
pubmed: 2224848
Nature. 2018 Mar 15;555(7696):377-381
pubmed: 29513649
Neuro Oncol. 2010 Jun;12(6):608-13
pubmed: 20156802
Nat Commun. 2013;4:2185
pubmed: 23887589
N Engl J Med. 2005 Aug 25;353(8):811-22
pubmed: 16120861
Invest New Drugs. 2002 Aug;20(3):241-51
pubmed: 12201487
Cell Stem Cell. 2008 Sep 11;3(3):265-78
pubmed: 18786414
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Radiat Oncol. 2014 Apr 23;9:95
pubmed: 24758192
Cancer Res. 2005 Aug 15;65(16):7301-9
pubmed: 16103081
Front Cell Neurosci. 2018 Nov 27;12:462
pubmed: 30542270
N Engl J Med. 1995 Mar 30;332(13):839-47
pubmed: 7661930
Int J Biochem Cell Biol. 2019 May;110:91-102
pubmed: 30849522
Drug Resist Updat. 2007 Feb-Apr;10(1-2):13-29
pubmed: 17303468
Lab Invest. 1992 Mar;66(3):303-13
pubmed: 1538585
Acta Neuropathol Commun. 2017 Aug 29;5(1):62
pubmed: 28851427
Cancer Genet. 2012 Dec;205(12):613-21
pubmed: 23238284
Cancer. 2005 Dec 15;104(12):2798-806
pubmed: 16288487
Sci Signal. 2009 Sep 08;2(87):re6
pubmed: 19738203
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Biol Ther. 2013 Apr;14(4):287-94
pubmed: 23358475
J Neurooncol. 2004 Oct;70(1):91-5
pubmed: 15527114
Cancer Res. 1999 Sep 1;59(17):4413-8
pubmed: 10485491
Am J Pathol. 2010 Sep;177(3):1491-502
pubmed: 20671264
Biochem J. 1998 Jun 1;332 ( Pt 2):281-92
pubmed: 9601053
Cells. 2021 Jan 18;10(1):
pubmed: 33477668
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biochem. 2002 Dec;132(6):853-7
pubmed: 12473186
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
Neuro Oncol. 2017 Feb 1;19(2):270-280
pubmed: 27571887
Int J Mol Sci. 2021 Jan 18;22(2):
pubmed: 33477674
N Engl J Med. 2005 Nov 10;353(19):2012-24
pubmed: 16282176
Front Neurosci. 2016 Apr 05;10:149
pubmed: 27092050
Sci Rep. 2021 Jan 8;11(1):207
pubmed: 33420238
Cell Stem Cell. 2012 Oct 5;11(4):471-6
pubmed: 23040476
Glia. 2002 Sep;39(3):193-206
pubmed: 12203386
J Cell Sci. 2011 Sep 15;124(Pt 18):3084-94
pubmed: 21878493
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Oncol. 2014 Aug;45(2):493-8
pubmed: 24841225
Methods Mol Biol. 2013;1052:1-11
pubmed: 23640252
J Biochem. 2002 Oct;132(4):509-11
pubmed: 12359062
Cell Stem Cell. 2008 Sep 11;3(3):289-300
pubmed: 18786416
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Nature. 2004 Feb 19;427(6976):740-4
pubmed: 14973487
World Neurosurg. 2013 Dec;80(6):e237-43
pubmed: 23395851
Int J Neuropsychopharmacol. 2015 Jul 29;19(1):
pubmed: 26224011
Neuro Oncol. 2006 Jan;8(1):47-52
pubmed: 16443947
Cell Struct Funct. 2001 Feb;26(1):25-35
pubmed: 11345501
Cell Stem Cell. 2008 Sep 11;3(3):279-88
pubmed: 18786415
Cancer Res. 1994 May 15;54(10):2794-9
pubmed: 8168112
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Brain Pathol. 2010 Jan;20(1):39-49
pubmed: 18947333
Am J Pathol. 2012 Oct;181(4):1126-41
pubmed: 22858156
Cancer Res. 2002 Jul 1;62(13):3729-35
pubmed: 12097282